Bondeson et al. (2015) employed the VHL ligand to create PROTACs targeting estrogen-related receptor alpha (ERRα) and the serine-threonine kinase RIPK2, and their activities were proven by the depletion of ERRα in breast cancer cells and depletion of RIPK2 in monocytes [302]. This evidence concerns the gene ESRRA and breast carcinoma.